Recent news releases
-
May 7, 2025 Apotex announces expansion of licensing agreement with Formosa Pharmaceuticals to Mexico for commercialization of clobetasol propionate ophthalmic suspension for the treatment of inflammation and pain following ocular surgery
-
Feb 24, 2025 Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal
-
Feb 5, 2025 Apotex, through its specialty pharma division, Searchlight, expands branded dermatology portfolio through the in-licensing of the Canadian rights to SEYSARA® (sarecycline) and FINJUVE™ (finasteride)
-
Feb 5, 2025 Apotex acquires US rights to PROVIGIL® (modafinil) and NUVIGIL® (armodafinil)
-
Feb 3, 2025 Apotex enters the growing Canadian health and wellness sector through the acquisition of CanPrev, a leading Canadian natural health company
-
Sep 5, 2024 Apotex Corp. is the first generic manufacturer to launch oxcarbazepine ER tablets in the United States
-
Sep 5, 2024 Apotex Corp. is the first generic manufacturer to launch dasatinib tablets in the United States
-
Aug 7, 2024 Apotex expands ophthalmic franchise through the acquisition of Canadian rights to APP13007 (clobetasol propionate ophthalmic suspension, 0.05%), a novel steroid for ophthalmology
-
Jul 3, 2024 Apotex Further Expands Oncology Franchise Through the Acquisition of Canadian Rights to Toripalimab
-
Jun 3, 2024 Apotex Completes Acquisition of Searchlight, a leading Canadian-based Specialty Innovative Branded Pharmaceutical Company